Flag of the European Union EU Clinical Trials Register Help

Clinical trials for gevokizumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: gevokizumab. Displaying page 1 of 1.
    EudraCT Number: 2013-002562-39 Sponsor Protocol Number: CL2-78989-018 Start Date*: 2013-10-10
    Sponsor Name:Institut de Recherches Internationales Servier (IRIS)
    Full Title: An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.
    Medical condition: Schnitzler syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10062908 Schnitzler's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003610-41 Sponsor Protocol Number: CL2-78989-011 Start Date*: 2015-03-20
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Dose-response study of gevokizumab (S78989) 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-bli...
    Medical condition: Diabetic kidney disease in patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) SK (Completed) BE (Completed) DE (Prematurely Ended) DK (Prematurely Ended) SE (Completed) ES (Completed) PT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001125-27 Sponsor Protocol Number: CL3-78989-002 Start Date*: 2013-01-15
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis EYEGUARD TM -B
    Medical condition: Behçet’s disease uveitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10071139 Behcet's uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) GR (Prematurely Ended) PT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-002778-38 Sponsor Protocol Number: CL2-78989-012 Start Date*: 2013-11-11
    Sponsor Name:Institut de Recherches Internationales Servier (IRIS)
    Full Title: A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis
    Medical condition: Giant cell arteritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Completed) GB (Completed) CZ (Completed) FI (Completed) DK (Prematurely Ended) BE (Completed) AT (Completed) IE (Prematurely Ended) EE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005772-34 Sponsor Protocol Number: CL2-78989-010 Start Date*: 2013-06-17
    Sponsor Name:Institut de Recherches Internationales Servier (IRIS)
    Full Title: A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis o...
    Medical condition: Polymyositis / Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) SE (Completed) DE (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004973-29 Sponsor Protocol Number: CL3-78989-019 Start Date*: 2014-08-13
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.
    Medical condition: chronic non-infectious uveitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10022557 Intermediate uveitis LLT
    18.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    18.0 100000004862 10036370 Posterior uveitis LLT
    18.0 100000004866 10071139 Behcet's uveitis LLT
    18.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    18.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    18.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) PT (Completed) ES (Completed) AT (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001610-42 Sponsor Protocol Number: X052130/CL3-78989-005 Start Date*: 2013-01-24
    Sponsor Name:XOMA (US) LLC
    Full Title: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 10015919 - Eye disorders 10066681 Acute uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Completed) GB (Prematurely Ended) ES (Completed) GR (Prematurely Ended) AT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001609-25 Sponsor Protocol Number: X052131/CL3-78989-006 Start Date*: 2013-01-02
    Sponsor Name:XOMA (US) LLC
    Full Title: A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan- uveitis Currently C...
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) PT (Completed) IT (Completed) GR (Prematurely Ended) ES (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002677-53 Sponsor Protocol Number: CL2-78989-009 Start Date*: 2012-12-19
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wa...
    Medical condition: Arterial wall inflammation in patients with marked atherosclerotic plaque inflammation
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10057703 Coronary atherosclerosis of non-autologous biological bypass graft LLT
    16.0 100000004849 10058152 Coronary atherosclerosis of bypass graft LLT
    16.0 100000004866 10018104 Generalized and unspecified atherosclerosis LLT
    16.0 100000004866 10002892 Aortic atherosclerosis LLT
    16.0 100000004849 10011093 Coronary atherosclerosis LLT
    16.0 100000004866 10003603 Atherosclerosis generalized LLT
    16.0 100000004849 10011095 Coronary atherosclerosis of native coronary artery LLT
    16.0 100000004866 10003605 Atherosclerosis of aorta LLT
    16.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    16.0 100000004849 10011094 Coronary atherosclerosis of autologous biological bypass graft LLT
    16.0 100000004849 10011076 Coronary artery atherosclerosis LLT
    16.0 100000004849 10011097 Coronary atherosclerosis of unspecified vessel LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 09:07:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA